Timber Pharmaceuticals Analyst Ratings
Timber Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/28/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 04/10/2023 | 263.04% | HC Wainwright & Co. | $1 → $11 | Reiterates | → Buy |
| 10/26/2022 | -67% | HC Wainwright & Co. | $1.5 → $1 | Maintains | Buy |
| 08/29/2022 | -67% | HC Wainwright & Co. | $1.5 → $1 | Maintains | Buy |
| 05/02/2022 | -50.5% | HC Wainwright & Co. | $2 → $1.5 | Maintains | Buy |
| 03/31/2022 | -33.99% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/28/2023 | — | HC Wainwright & Co. | 降級 | 買入 → 中性 | |
| 2023 年 10 月 4 日 | 263.04% | HC Wainwright & Co. | $1 → 11 美元 | 重申 | → 購買 |
| 2022 年 10 月 26 日 | -67% | HC Wainwright & Co. | 1.5 美元 → 1 美元 | 維護 | 購買 |
| 08/29/2022 | -67% | HC Wainwright & Co. | 1.5 美元 → 1 美元 | 維護 | 購買 |
| 05/02/2022 | -50.5% | HC Wainwright & Co. | $2 → 1.5 美元 | 維護 | 購買 |
| 03/31/2022 | -33.99% | HC Wainwright & Co. | → 2 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Timber Pharmaceuticals (TMBR)?
Timber Pharmicals（TMBR）的目標價格是多少？
The latest price target for Timber Pharmaceuticals (AMEX: TMBR) was reported by HC Wainwright & Co. on August 28, 2023. The analyst firm set a price target for $0.00 expecting TMBR to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月28日公佈了Timber Pharmicals（美國證券交易所股票代碼：TMBR）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計TMBR將在12個月內跌至-100.00％（可能下跌-100.00％）。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Timber Pharmaceuticals (TMBR)?
Timber Pharmicals（TMBR）的最新分析師評級是多少？
The latest analyst rating for Timber Pharmaceuticals (AMEX: TMBR) was provided by HC Wainwright & Co., and Timber Pharmaceuticals downgraded their neutral rating.
Timber Pharmicals（美國證券交易所股票代碼：TMBR）的最新分析師評級由HC Wainwright & Co. 提供，Timber Pharmicals下調了中性評級。
When is the next analyst rating going to be posted or updated for Timber Pharmaceuticals (TMBR)?
Timber Pharmicals（TMBR）的下一次分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Timber Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Timber Pharmaceuticals was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Timber Pharmicals的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Timber Pharmicals的最後一次評級是在2023年8月28日提交的，因此你應該預計下一個評級將在2024年8月28日左右公佈。
Is the Analyst Rating Timber Pharmaceuticals (TMBR) correct?
Timber Pharmicals（TMBR）的分析師評級是否正確？
While ratings are subjective and will change, the latest Timber Pharmaceuticals (TMBR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Timber Pharmaceuticals (TMBR) is trading at is $3.03, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Timber Pharmicals（TMBR）評級被下調，目標股價爲0.00美元至0.00美元。Timber Pharmicals（TMBR）目前的交易價格爲3.03美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。